Question special

Several healthcare practices exclude minority patients. Today, as we focus on making medicine more inclusive for minority patients, I would like us to consider the underrepresentation of racial and ethnic minorities in clinical trials and research studies that inform evidence-based medical policies and practices. We often see studies of homogenous sample sizes that do not include minority populations. Disparities pervade clinical trial recruitment and participation, resulting in nongeneralizable findings. Being understudied continues to affect the care available to us. Only a few studies depict the safety and efficacy of therapies in minority patient populations, effectively excluding us from the benefits of these interventions. This disheartening, pertinent ProPublica article comes to mind: What sustainable solutions can we consider to overcome barriers to diversity in clinical trials and other research studies?